Re-screening for novel CD40-TRAF6 interaction inhibitors (TRAF-STOPs 2.0)
- Laufzeit
-
2021 – 2021
- Budget
-
€ 405.710
- Indikation
Atherosklerose
- Therapeutic Principle
Drug
- Principal Investigator
-
Dorothee Atzler, Christian Weber, Esther Lutgens (Klinikum der Universität München)
